Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder – 3 Month Extension Study (ZYL-730-02)

This 3-month extension randomised study compares intranasal esketamine (56 or 84 mg according to Product Monograph; 8 administrations over 3 months) plus Almond Therapy versus esketamine plus treatment as usual in participants previously enrolled in ZYL-730-01.

Almond Therapy comprises up to 12 remote sessions tailored to participants plus supportive text messages; participants also receive up to 9 in-person visits and remote MADRS assessments by an independent assessor.